When and why is apixaban (Eliquis) typically prescribed?

When and Why Apixaban is Prescribed

Apixaban (Eliquis) is prescribed primarily to prevent stroke in patients with atrial fibrillation and to treat or prevent venous blood clots (deep vein thrombosis and pulmonary embolism). 1

Primary Indications

1. Atrial Fibrillation - Stroke Prevention

Apixaban is the most commonly prescribed indication for preventing stroke and systemic embolism in patients with nonvalvular atrial fibrillation 2, 1.

Dosing for atrial fibrillation:

• Standard dose: 5 mg twice daily for most patients 1
• Reduced dose: 2.5 mg twice daily if the patient has at least 2 of the following 3 criteria 1:
  • Age ≥80 years
  • Body weight ≤60 kg (132 lbs)
  • Serum creatinine ≥1.5 mg/dL

The decision to anticoagulate is based on stroke risk assessment using the CHA₂DS₂-VASc score (scoring for congestive heart failure, hypertension, age ≥75 years [2 points], diabetes, prior stroke/TIA [2 points], vascular disease, age 65-74 years, and female sex) 2. Real-world evidence demonstrates that apixaban has superior safety compared to warfarin and other direct oral anticoagulants, with significantly lower rates of major bleeding while maintaining excellent stroke prevention 3.

Critical caveat: Apixaban is NOT for patients with mechanical heart valves or moderate-to-severe mitral stenosis 1. This is explicitly contraindicated.

2. Venous Thromboembolism (VTE) Treatment

Apixaban treats deep vein thrombosis (DVT) and pulmonary embolism (PE) 1.

Treatment dosing:

• First 7 days: 10 mg twice daily (loading phase)
• After 7 days: 5 mg twice daily (maintenance phase) 1

The 2022 ITAC guidelines upgraded apixaban to Grade 1A recommendation for cancer-associated thrombosis, placing it on equal footing with low-molecular-weight heparin 4. This represents a significant shift, as apixaban (along with other direct oral anticoagulants) is now considered first-line for most patients with cancer-associated VTE, except those at high risk of gastrointestinal or genitourinary bleeding 4.

3. VTE Prevention After Orthopedic Surgery

Apixaban prevents blood clots following hip or knee replacement surgery 1, 5.

Prophylaxis dosing:

• 2.5 mg twice daily
• Start 12-24 hours after surgery
• Continue for 35 days after hip replacement or 12 days after knee replacement 1

4. Secondary Prevention of Recurrent VTE

After completing at least 6 months of anticoagulation for DVT/PE, apixaban prevents recurrence 1.

Extended prophylaxis dosing:

• 2.5 mg twice daily (reduced intensity for long-term use) 1

Recent evidence from the API-CAT trial (2025) demonstrates that in patients with cancer-associated VTE, extended treatment with reduced-dose apixaban (2.5 mg twice daily) is noninferior to full-dose for preventing recurrence while significantly reducing bleeding complications 6.

Key Advantages Over Warfarin

Apixaban offers several practical advantages:

• No routine blood monitoring required (unlike warfarin's INR checks)
• Predictable pharmacokinetics - works consistently without dietary restrictions 7
• Rapid onset (peak effect in 3-4 hours) and offset (12-hour half-life) 7
• Lower bleeding risk, particularly intracranial hemorrhage, compared to warfarin 2, 3

Critical Drug Interactions and Contraindications

Avoid apixaban with:

• Combined strong CYP3A4 inhibitors AND P-glycoprotein inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin) - these require dose reduction to 2.5 mg twice daily if patient is on standard 5 mg dose 2
• Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's wort) - these significantly reduce apixaban levels 2

Dose adjustment for renal impairment:

• Creatinine clearance >50 mL/min: no adjustment needed
• The dose reduction criteria for atrial fibrillation already account for renal dysfunction (serum creatinine ≥1.5 mg/dL is one of the three criteria) 1

Common Pitfalls to Avoid

1. Off-label underdosing is common but potentially harmful - approximately 15-17% of elderly patients receive inappropriately reduced doses, which may increase mortality risk 8

2. Don't double up on missed doses - if a dose is missed, take it as soon as remembered on the same day, then resume the twice-daily schedule 1

3. Surgical interruption requires planning - stop apixaban 48 hours before high-bleeding-risk procedures and 24 hours before low-bleeding-risk procedures 1

4. Spinal/epidural procedures carry special risk - patients receiving neuraxial anesthesia or spinal puncture while on apixaban risk epidural hematoma and permanent paralysis 1

5. Switching anticoagulants requires specific protocols - when transitioning from warfarin, start apixaban only when INR <2.0; when switching to warfarin, use bridging with parenteral anticoagulation 1

The evidence strongly supports apixaban as a first-line anticoagulant across multiple indications, with the 2023 ACC/AHA guidelines 2 and 2022 ITAC guidelines 4 providing Grade 1A recommendations for its use in atrial fibrillation and cancer-associated thrombosis respectively.